IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 2,611 Cr.
- Current Price ₹ 445
- High / Low ₹ 463 / 272
- Stock P/E 18.6
- Book Value ₹ 257
- Dividend Yield 0.90 %
- ROCE 13.6 %
- ROE 9.66 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 20.0%
- Promoter holding has increased by 4.50% over last quarter.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
471 | 482 | 564 | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | |
402 | 392 | 468 | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,991 | |
Operating Profit | 69 | 89 | 96 | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 |
OPM % | 15% | 18% | 17% | 3% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% |
2 | 3 | 1 | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 26 | |
Interest | 43 | 57 | 60 | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 |
Depreciation | 24 | 31 | 32 | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 |
Profit before tax | 4 | 3 | 5 | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 |
Tax % | -25% | 46% | 35% | 12% | -4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% |
Net Profit | 5 | 2 | 3 | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 |
EPS in Rs | 1.85 | 0.61 | 1.15 | -13.99 | -7.12 | 0.83 | 4.93 | 41.61 | 63.51 | 75.73 | 28.22 | 23.84 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 18% |
3 Years: | 5% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 56% |
5 Years: | 38% |
3 Years: | -27% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | 36% |
5 Years: | 35% |
3 Years: | 6% |
1 Year: | 19% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 28% |
3 Years: | 20% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | 31 | 49 | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | |
Reserves | 143 | 142 | 160 | 154 | 129 | 132 | 160 | 408 | 747 | 1,202 | 1,332 | 1,448 |
394 | 400 | 357 | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | |
124 | 159 | 195 | 100 | 135 | 182 | 214 | 193 | 306 | 347 | 526 | 434 | |
Total Liabilities | 687 | 727 | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 |
462 | 430 | 411 | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 760 | |
CWIP | 12 | 32 | 33 | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 81 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 |
213 | 265 | 297 | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | |
Total Assets | 687 | 727 | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 53 | 78 | -47 | 18 | 83 | 120 | 273 | 471 | 380 | 91 | 123 | |
-87 | -18 | -12 | -5 | -27 | -23 | -50 | -63 | -184 | -317 | -120 | -119 | |
23 | -32 | -66 | 50 | 9 | -60 | -70 | -197 | -272 | -58 | -2 | -4 | |
Net Cash Flow | -9 | 3 | 1 | -2 | -0 | 1 | -1 | 13 | 15 | 4 | -31 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 17 | 27 | 32 | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 |
Inventory Days | 160 | 199 | 190 | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 |
Days Payable | 97 | 116 | 119 | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 |
Cash Conversion Cycle | 80 | 110 | 103 | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 |
Working Capital Days | 32 | 82 | 58 | 173 | 125 | 108 | 73 | 57 | 57 | 66 | 78 | 86 |
ROCE % | 9% | 11% | 11% | -3% | 4% | 12% | 15% | 56% | 69% | 54% | 18% | 14% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
17 May - Transcript of Earnings Conference Call, post declaration of audited financial results for the quarter and year ended 31st March 2023
- Submission Of Voting Results & Scrutinizer'S Report Of Postal Ballot Of IOL Chemicals And Pharmaceuticals Limited 12 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 May - Audio Recording of Analysts/Investors Call pertaining to the Financial Results 4Q & FY23
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 May - Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the Company is organizing an analyst /investor conference call on Tuesday, 09th May, 2023 at 3:00 …
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
Pharma Segment - APIs (~46% of revenues) [1]
The company manufactures various APIs for various therapeutic areas such as Pain management, anti-diabetic, anti-platelet, anti-cholesterol and others. It is the largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share. [2] In FY22, Ibuprofen accounted for ~65% of revenues of the company's pharma segment.